Evidence map›Paper›PMID 16575534›Full record

Trial reportJournal of neuro-oncology2006

Cystemustine in recurrent high grade glioma.

X Durando, E Thivat, H Roché, J O Bay, J-J Lemaire, P Verrelle, M-A Lentz, J Chazal, H Curé, P Chollet

Erratum issuedAbstract readClinical TrialClinical Trial, Phase II
PubMed Publisher
In one paragraph

Trial report in Journal of neuro-oncology, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
0.6field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it, 10 citations in OpenAlex.

  1. Guideline
4 · The record

Corrections and comments

  • Erratum issued
    Lentz, MA [removed]
5 · Who and what money

Authors and funding

10 authors at 5 institutions in 2 countries.

X DurandoCentre Jean Perrin, 63011, Clermont-Ferrand Cédex, France.
E Thivat
H Roché
J O Bay
J-J Lemaire
P Verrelle
M-A Lentz
J Chazal
H Curé
P Chollet
Centre Jean Perrin · FRCentre Hospitalier Universitaire de Clermont-Ferrand · FRInserm · FREuropean Organisation for Research and Treatment of Cancer · NLInstitut Claudius Regaud · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In this study, we have assessed the efficacy of a nitrosourea, cystemustine, in treating patients with recurrent high grade glioma with overall survival analysis as primary end-point. Forty-eight patients with recurrent high grade glioma (24 glioblastomas, 17 astrocytomas and 5 oligodendrogliomas) were treated every 2 weeks with 60 mg/m2 cystemustine by a 15 min-infusion. The median number of treatment cycles was 4 (range 1-17). The median overall survival was 8.3 months (range 1-97) and the 6- and 12-month overall survival rates were 55.3% (95% CI, 41.3-68.6%) and 29.8% (95% CI, 18.6-44.0%), respectively. The objective response rate was 18.8% (95% CI, 7.7-29.9%), and 54.2% of patients had stable disease (95% CI, 40.1-68.3%). Multivariate analysis showed that WHO performance status, histology and response to cystemustine were significant prognostic factors for survival of patients with recurrent glioma. In conclusion, cystemustine has encouraging activity for patients with recurrent high grade glioma.

Indexed as

AdultAgedAged, 80 and overAntineoplastic AgentsBrain NeoplasmsFemaleGliomaHumansMaleMiddle AgedNeoplasm Recurrence, LocalNitrosourea CompoundsPrognosisSurvival AnalysisSurvival RateTreatment OutcomeAntineoplastic AgentsN'-(2-chloroethyl)-N-(2-(methylsulfonyl)ethyl)-N'-nitrosoureaNitrosourea Compounds

Identifiers

PMID16575534
OpenAlexW2084761248

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.